CD99 engagement: An effective therapeutic strategy for Ewing tumors

K. Scotlandi, N. Baldini, V. Cerisano, M. C. Manara, S. Benini, M. Serra, P. L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, A. Bernard, P. Picci

Research output: Contribution to journalArticle

Abstract

CD99 is a M(r) 32,000 transmembrane molecule that shows a high level of expression on cells of the hemopoietic system as well as on Ewing tumor cells. Within the hematopoietic system, CD99 has been implicated in cell adhesion and cell death, participating in this way in the differentiation of T-cell precursors. In this study, we demonstrate that engagement of CD99 significantly inhibits the in vitro and in vivo growth ability of Ewing tumor cells by delivering an apoptotic stimulus and reducing the malignant potential of these cells. Moreover, we show that anti-CD99 monoclonal antibodies may be advantageously used in association with conventional anticancer agents. These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement.

Original languageEnglish
Pages (from-to)5134-5142
Number of pages9
JournalCancer Research
Volume60
Issue number18
Publication statusPublished - Sep 15 2000

Fingerprint

Ewing's Sarcoma
T-Lymphoid Precursor Cells
Hematopoietic System
Therapeutics
Cell Adhesion
Antineoplastic Agents
Patient Care
Cell Death
Monoclonal Antibodies
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD99 engagement : An effective therapeutic strategy for Ewing tumors. / Scotlandi, K.; Baldini, N.; Cerisano, V.; Manara, M. C.; Benini, S.; Serra, M.; Lollini, P. L.; Nanni, P.; Nicoletti, G.; Bernard, G.; Bernard, A.; Picci, P.

In: Cancer Research, Vol. 60, No. 18, 15.09.2000, p. 5134-5142.

Research output: Contribution to journalArticle

Scotlandi, K, Baldini, N, Cerisano, V, Manara, MC, Benini, S, Serra, M, Lollini, PL, Nanni, P, Nicoletti, G, Bernard, G, Bernard, A & Picci, P 2000, 'CD99 engagement: An effective therapeutic strategy for Ewing tumors', Cancer Research, vol. 60, no. 18, pp. 5134-5142.
Scotlandi, K. ; Baldini, N. ; Cerisano, V. ; Manara, M. C. ; Benini, S. ; Serra, M. ; Lollini, P. L. ; Nanni, P. ; Nicoletti, G. ; Bernard, G. ; Bernard, A. ; Picci, P. / CD99 engagement : An effective therapeutic strategy for Ewing tumors. In: Cancer Research. 2000 ; Vol. 60, No. 18. pp. 5134-5142.
@article{c04be72bd4ef4c12ab0a1b8405584c0e,
title = "CD99 engagement: An effective therapeutic strategy for Ewing tumors",
abstract = "CD99 is a M(r) 32,000 transmembrane molecule that shows a high level of expression on cells of the hemopoietic system as well as on Ewing tumor cells. Within the hematopoietic system, CD99 has been implicated in cell adhesion and cell death, participating in this way in the differentiation of T-cell precursors. In this study, we demonstrate that engagement of CD99 significantly inhibits the in vitro and in vivo growth ability of Ewing tumor cells by delivering an apoptotic stimulus and reducing the malignant potential of these cells. Moreover, we show that anti-CD99 monoclonal antibodies may be advantageously used in association with conventional anticancer agents. These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement.",
author = "K. Scotlandi and N. Baldini and V. Cerisano and Manara, {M. C.} and S. Benini and M. Serra and Lollini, {P. L.} and P. Nanni and G. Nicoletti and G. Bernard and A. Bernard and P. Picci",
year = "2000",
month = "9",
day = "15",
language = "English",
volume = "60",
pages = "5134--5142",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - CD99 engagement

T2 - An effective therapeutic strategy for Ewing tumors

AU - Scotlandi, K.

AU - Baldini, N.

AU - Cerisano, V.

AU - Manara, M. C.

AU - Benini, S.

AU - Serra, M.

AU - Lollini, P. L.

AU - Nanni, P.

AU - Nicoletti, G.

AU - Bernard, G.

AU - Bernard, A.

AU - Picci, P.

PY - 2000/9/15

Y1 - 2000/9/15

N2 - CD99 is a M(r) 32,000 transmembrane molecule that shows a high level of expression on cells of the hemopoietic system as well as on Ewing tumor cells. Within the hematopoietic system, CD99 has been implicated in cell adhesion and cell death, participating in this way in the differentiation of T-cell precursors. In this study, we demonstrate that engagement of CD99 significantly inhibits the in vitro and in vivo growth ability of Ewing tumor cells by delivering an apoptotic stimulus and reducing the malignant potential of these cells. Moreover, we show that anti-CD99 monoclonal antibodies may be advantageously used in association with conventional anticancer agents. These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement.

AB - CD99 is a M(r) 32,000 transmembrane molecule that shows a high level of expression on cells of the hemopoietic system as well as on Ewing tumor cells. Within the hematopoietic system, CD99 has been implicated in cell adhesion and cell death, participating in this way in the differentiation of T-cell precursors. In this study, we demonstrate that engagement of CD99 significantly inhibits the in vitro and in vivo growth ability of Ewing tumor cells by delivering an apoptotic stimulus and reducing the malignant potential of these cells. Moreover, we show that anti-CD99 monoclonal antibodies may be advantageously used in association with conventional anticancer agents. These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement.

UR - http://www.scopus.com/inward/record.url?scp=0034665335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034665335&partnerID=8YFLogxK

M3 - Article

C2 - 11016640

AN - SCOPUS:0034665335

VL - 60

SP - 5134

EP - 5142

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 18

ER -